AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02507310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thermostat
Description: ambient temperature as modified by thermostat
Study NCT02507310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermostat
Description: ambient temperature as modified by thermostat
Study NCT04440943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-527
Description: CDX-527 is administered by infusion every 2 weeks
Study NCT04215341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
Study NCT04669405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity laser therapy
Description: A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
Study NCT04669405 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Exercise
Description: A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
Study NCT04669405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
Study NCT01014338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril
Description: 10mg od
Study NCT01014338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: placebo
Study NCT03898687 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SLN Biopsy with Magtrace®/Sentimag®
Description: Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
Study NCT04127539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong & Steady exercise program
Description: The community-based group exercise program S\&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S\&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S\&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
Study NCT01599325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
Study NCT00483249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Branched Stent-Graft
Description: Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
Study NCT02987140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluations
Description: Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
Study NCT02987140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical evaluations
Description: Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
Study NCT02374255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GoC intervention
Description: Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
Study NCT00583531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: Oral, 2 grams TID in sachets for 4 weeks
Study NCT05226052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (Floratil 600mg)
Description: PGIC and PGIS assessment
Study NCT05226052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3 capsules of placebo
Description: PGIC and PGIS assessment
Study NCT01791179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive substance abuse services
Study NCT01119703 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tetanus & Diphtheria booster vaccine (Td)
Description: Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose
Study NCT01119703 — intervention group
Intervention type: BIOLOGICAL
Intervention: TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]
Description: TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)
Study NCT00781898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot naltrexone
Description: Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
Study NCT00781898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual (TAU) community treatment provided to the participant
Study NCT01119703 — intervention group
Intervention type: BIOLOGICAL
Intervention: Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)
Description: Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
Study NCT02828605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Interactive Platform (VIP) Transplant
Study NCT01972139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation using the Symplicity Renal Denervation System
Description: Subjects randomized to the renal denervation group underwent angiography and renal denervation.
Study NCT01972139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham Renal Denervation
Description: Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
Study NCT01972139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Renal Angiography
Description: Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
Study NCT02932423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product C
Description: Beverage with 33 g/L sugar and sweetener
Study NCT02868996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Intravenous DM199
Study NCT04019054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)
Description: iTBS delivered to vmPFC for active treatment of spider phobia.
Study NCT04019054 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS), vertex
Description: iTBS delivered to vertex for placebo treatment of spider phobia.
Study NCT04096677 — intervention group
Intervention type: PROCEDURE
Intervention: hysteroscpy
Study NCT03673982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCASK
Description: Materials and support to aid transitions
Study NCT01801917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet for oral administration
Study NCT01801917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
Study NCT03318627 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sterile Spring Scale
Description: Measuring intraoperative tension of tendon of rotator cuff tear
Study NCT00809588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, lethally irradiated melanoma cells
Description: Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
Study NCT03583294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI pelvic
Description: Pelvic MRI
Study NCT02932423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product D
Description: Beverage with 47 g/L sugar and sweetener
Study NCT00826137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin and fructo-oligosaccharides.
Description: Supplement during antibiotic treatment+14 days.
Study NCT00826137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is base powder of product with no oligosaccharides.
Study NCT02932423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparative product F
Description: Beverage with 98 g/L sugar
Study NCT01529684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radio-labeled OSI-906
Description: Part A: oral solution of 14C-OSI-906
Study NCT01529684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Part B: oral tablets OSI-906
Study NCT00669396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper T380 IUD
Description: Copper T380 IUD
Study NCT00669396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel
Description: 1.5 mg
Study NCT02785484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label with constituent disclosure message
Description: Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
Study NCT02785484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Label with litter message
Description: Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
Study NCT03599076 — intervention group
Intervention type: OTHER
Intervention: HD Wear
Description: Wearable sensor system for monitoring Huntington's chorea during activities of daily living
Study NCT05095285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: * Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~* Common procedure steps:~  * Legal representatives of the infants will sign an informed consent form.~ * İncubator cover and nesting~ * Endotracheal suction(ES) was performed in the supine position.~ * ES was done at the time of care the baby needed.~ * No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~ * Aspiration was performed sterile at 80 mmHg pressure.~ * A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~ * The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~ * Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded.
Study NCT05095285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum
Description: * Common procedure steps~* In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue.
Study NCT01418105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videofluroscopic swallow study (VFSS)
Description: Barium, radiation
Study NCT01418105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical spine isometric exercises
Description: patients with cervical scoliosis will execute isometric exercises of the cervical spine
Study NCT01418105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic endoscopic esophageal study (FEES)
Description: food for swallowing
Study NCT02963818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone breathalyzer device/app use
Description: Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
Study NCT02963818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC estimator app use
Description: Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
Study NCT02963818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging procedure
Description: Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
Study NCT00420537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine trough levels between 100 and 150
Study NCT04585945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positive for SARS-CoV-2 infection
Description: Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
Study NCT03194685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10101-01
Description: FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.
Study NCT00420537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine trough levels between 40 and 90 ng/ml
Study NCT00420537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: mycophenolate with low doses
Study NCT00420537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study NCT06240286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.
Study NCT06240286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.
Study NCT06240286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.
Study NCT06240286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
Study NCT00404911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFG therapy
Description: MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
Study NCT00404911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
Study NCT00404911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
Study NCT01078532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART PHR
Description: Patient receives an active PHR
Study NCT01078532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: Usual passive PHR
Study NCT01715935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
Study NCT02373657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction in soap-making and hygiene education
Study NCT01880463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Study NCT01880463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Study NCT01880463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Study NCT01880463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Study NCT01880463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Study NCT01880463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Study NCT02892279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure
Description: Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
Study NCT01519479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
Study NCT01519479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
Study NCT03713450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control with imaging guidance
Description: Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile).
Study NCT03713450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control without imaging guidance
Description: Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile).
Study NCT03027596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning